William J. Sandborn files SEC Form 4 disclosures for Ventyx Biosciences, Inc.. They have made 10 open-market trades across 1 company since 2022, most recently 2023-08-31.
CIK 0001923805
Unrated. We grade insiders only on stock they chose to buy on the open market. Grants, option exercises and vesting say nothing about timing, so they don't count — which is why someone can file often and still have no grade. It isn't a bad sign: unrated buys beat every graded tier below A.
0 open-market purchases, against 10 sales. Too few scored purchases to measure a record yet.
| Ticker | Shares | Value |
|---|---|---|
| VTYX | 60,289 | $844K |
Shares reported on the most recent Form 4, priced at the 2023-09-01 close.
| Ticker | Type | Traded | Filed | Price | Value | 7d Stock | 30d Stock | 90d Stock |
|---|---|---|---|---|---|---|---|---|
| VTYX | SELL | 2023-08-31 | 2023-09-01 | $33.64 | $400K | +4.0% | -6.7% | -93.5% |
| VTYX | SELL | 2023-08-08 | 2023-08-08 | $32.80 | $183K | -5.4% | +2.0% | -57.0% |
| VTYX | SELL | 2023-07-31 | 2023-08-01 | $37.16 | $884K | -8.7% | -8.4% | -60.7% |
| VTYX | SELL | 2023-07-03 | 2023-07-05 | $40.00 | $615K | -4.3% | -4.7% | -18.7% |
| VTYX | SELL | 2023-06-23 | 2023-06-27 | $32.70 | $706K | +15.8% | +11.3% | +5.9% |
| VTYX | SELL | 2023-06-15 | 2023-06-16 | $34.04 | $200K | +0.9% | +12.6% | +10.2% |
| VTYX | SELL | 2023-05-31 | 2023-06-01 | $34.26 | $728K | -0.6% | +18.2% | -2.3% |
| VTYX | SELL | 2023-05-15 | 2023-05-16 | $36.34 | $199K | +0.6% | -2.4% | -6.1% |
| VTYX | SELL | 2023-04-28 | 2023-05-01 | $36.96 | $798K | -3.9% | -11.8% | -5.2% |
| VTYX | SELL | 2022-12-14 | 2022-12-16 | $33.87 | $2.9M | +0.8% | +3.7% | +11.3% |
Grouped by shared companies and similar filing behaviour. This is a similarity measure, not a ranking or a performance signal.